Compagnie Gervais Danone

Ar2i Sa - Analyses - Recherches Et Innovation Instrumentale

Fractales Biotech

Institut De Recherches Franctales

Eric Postaire

Chantal Cayuela

Jacques Sauzieres

Marie-Christine Degivry

Jean-Michel Antoine

Claude Andrieux

Bernard Dugas

Pascal Delvordre

Christian Sarbach

Christian Latge

Nathalie Dugas

Alphonse Calenda

Benjamin Bonavida

Corinne Guerin-Danan

Christine Bouley

Corinne Regnault

Monique Rock-Arveiller

Valerie Stella

Michel Brack

The invention concerns the use ofin a composition for oral administration to enhance immunity specific to pathogenic micro-organisms. Said composition can in particular be a food or a food supplement.

[object Object]

The invention concerns lactic acid bacteria strains capable of regulating the production of NO and inflammatory cytokines by enterocytes, depending on the inflammatory condition of said enterocytes. The strains can also be incorporated in food supplements such as fermented dairy products used for regulating inflammatory response and non-specific immunity.

Selection and uses of lactic acid bacteria strains modulating non-specific immunity

The object of the invention is to propose a novel biomarker for stress states, which biomarker is highly meaningful and capable of enabling quantitative measurements to be made of stress levels. To do this, it has been found, surprisingly, that the air at the end of a person's breathing out, known as 'alveolar' air, contains fluorine compounds when that person has been subjected to various stress states. More precisely, the present invention provides components based on fluorine compounds, in particular fluorinated chloroalkanes, used as biomarkers of stress states.

Biological marker for stress states

The invention concerns lactic acid bacteria with anxiolytic properties and not inducing sedative effect. Said lactic acid bacteria are useful in particular for preparing foods or medicines.

Lactic acid bacteria with anxiolytic properties and uses thereof

The invention concerns novel therapeutic uses of heterologous superoxide dismutase (HSD) for preparing medicines for treating diseases in which cell and organic degeneration is observed, and a method for selecting said HSD.

Therapeutic uses of heterologous superoxide dismutase (HSD), and method for selecting said HSD

DN 114-001 is a bacterial agent known for its utility in the fermentation of milk products. A fermented milk product comprising as the sole bacterial agent DN 114-001 is effective in reducing the number of rotavirus associated diarrhea episodes experienced by infants up to 24 months of age. In particular, the number of rotavirus associated diarrhea episodes, as well as their severity and duration is reduced in children receiving milk products fermented with DN 114-001, present in the fermented milk product in amounts of at least 10 CFU/g. may be the sole bacterial agent present in the fermented milk product, and yet effective reduction of diarrhea episodes associated with rotavirus infection is obtained.

Method and composition for treatment of infant diarrhea

Pharmaceutical compositions containing a superoxide dismutase

Growing community of inventors

Vanves, France

Eric Postaire